您的位置: 首页 > 农业专利 > 详情页

CHROMENE DERIVATIVES SUBSTITUTED BY ALKOXIDE AS INHIBITORS OF THE TCR-NCK INTERACTION
专利权人:
ARTAKS BIOFARMA INK.
发明人:
GAKHETE MATEOS Andres (US),ГАХЕТЕ МАТЕОС Андрес (US),KASTRO PALOMINO Khulio (ES),КАСТРО ПАЛОМИНО Хулио (ES),MARTI KLAUSEL Luk (US),МАРТИ КЛАУСЕЛЬ Лук (US),TORMO KARULYA Damiya (US),ТОРМО КАРУЛЬЯ Дамия,GAKHETE MATEOS Andres,ГАХЕТЕ МАТЕОС Андрес,KASTRO PALOMINO Khulio,КАСТРО ПАЛОМИНО Хулио,MARTI KLAUSEL Luk,МАРТИ КЛАУСЕЛЬ Лук,TORMO KARULYA Damiya
申请号:
RU2016118037
公开号:
RU0002658910C2
申请日:
2014.10.20
申请国别(地区):
RU
年份:
2018
代理人:
摘要:
FIELD: chemistry.SUBSTANCE: invention relates to a group of compounds of formula (I) containing a chromene core, wherein: R1 is selected from hydrogen and substituted or unsubstituted C1-C6 alkyl; R2 and R3 are independently selected from hydrogen and substituted or unsubstituted C1-C6 alkyl; or R2 and R3 together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocycle, wherein the heterocycle is a stable monocyclic or bicyclic radical containing from 3 to 15 members which is unsaturated, saturated or partially saturated and which consists of carbon atoms and at least one heteroatom selected from the following group: nitrogen, oxygen or sulfur; R4 represents a halogen; each C1-C6 alkyl is optionally and independently substituted with one or more substituents selected from halogen, hydroxyl, carboxyl, carbonyl, cyano, nitro, mercapto, C3-C6 cycloalkyl and NR'R'', where R' and R'' are independently selected from H and unsubstituted C1-C4 alkyl; each C3-C6 cycloalkyl and heterocycle is optionally and independently substituted with one or more substituents selected from halogen, hydroxyl, carboxyl, carbonyl, cyano, nitro, mercapto and unsubstituted C1-C4 alkyl; or a pharmaceutically acceptable salt thereof, with the proviso that the compound of formula (I) is not 1-((4-(4-fluorophenyl)-6-methoxy-2H-chromen-3-yl)methyl)pyrrolidine, and their production method..EFFECT: compounds of formula I have the ability to inhibit lymphocyte proliferation mediated by the interaction of Nck with TCR, and therefore the invention also relates to the use of said compounds for the treatment of diseases or conditions, in which said interaction causes complications such as graft rejection reactions, immune or autoimmune diseases, inflammatory diseases or proliferative diseases, and the invention relates to pharmaceutical compositions based on compounds of formula I.42 cl, 3 dwg, 2 tbl, 5 exИзобретение относится к группе соединений формулы (I), соде
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充